Mild oxidative stress induced by a low dose of cisplatin contributes to the escape of TRAIL-mediated apoptosis in the ovarian cancer SKOV3 cell line

Lu,Jinzhi; Zhang,Lei; Xie,Fang; Zhu,Liya; Li,Xiaolan; Ouyang,Jingping; He,Xiaohua; Han,Song; Yi,Cunjian

doi:10.3892/or.2016.4702

Mild oxidative stress induced by a low dose of cisplatin contributes to the escape of TRAIL-mediated apoptosis in the ovarian cancer SKOV3 cell line

Authors:
- Jinzhi Lu
- Lei Zhang
- Fang Xie
- Liya Zhu
- Xiaolan Li
- Jingping Ouyang
- Xiaohua He
- Song Han
- Cunjian Yi
View Affiliations

Affiliations: Department of Laboratory Medicine, Jingzhou First People's Hospital, Jingzhou, Hubei, P.R. China, Department of Obstetrics and Gynecology, Jingzhou First People's Hospital, Jingzhou, Hubei, P.R. China, Department of Obstetrics and Gynecology, Yichang Second People's Hospital, Yichang, Hubei, P.R. China, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei, P.R. China
Published online on: March 23, 2016 https://doi.org/10.3892/or.2016.4702
Pages: 3427-3434

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor (TNF)-related apoptosis‑inducing ligand (TRAIL) is expressed in ovarian tissue and is widely thought to exhibit strong antitumor activity in a variety of tumor cell types. Therefore, we hypothesized that the cisplatin resistance of ovarian cancer is linked to the ability to escape from TRAIL-mediated apoptosis. We demonstrated that cisplatin-resistant ovarian cancer cell line SKOV3/DDP tolerated treatment with TRAIL, in contrast to the cisplatin‑sensitive ovarian cancer cell line SKOV3. SKOV3/DDP cells exhibited a much higher cell viability and a lower apoptosis rate than SKOV3 cells after treatment with TRAIL. To determine whether cisplatin induced the tolerance of TRAIL, we pretreated the SKOV3 cells with cisplatin in the presence of TRAIL. This revealed that a low dose of cisplatin (1 µM) increased the TRAIL tolerance of SKOV3 cells. Furthermore, cisplatin induced oxidative stress in both the SKOV3/DDP and SKOV3 cells, although the oxidative stress level of the SKOV3/DDP cells was generally much higher than that noted in the SKOV3 cells. Similarly, a low dose of hydrogen peroxide increased the TRAIL tolerance in SKOV3 cells. Notably, the TRAIL tolerance in the SKOV3 and SKOV3/DDP cells could be abrogated by the oxidative stress scavenger N-acetyl-cysteine. These results suggest that a low dose of cisplatin induces the tolerance of TRAIL in SKOV3 cells at least partly, depending on the oxidative stress signaling pathway.

View Figures

View References

1	Kimberley FC and Screaton GR: Following a TRAIL: Update on a ligand and its five receptors. Cell Res. 14:359–372. 2004. View Article : Google Scholar : PubMed/NCBI
2	Bernard D, Quatannens B, Vandenbunder B and Abbadie C: Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem. 276:27322–27328. 2001. View Article : Google Scholar : PubMed/NCBI
3	Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
4	Li X, Ling V and Li PC: Same-single-cell analysis for the study of drug efflux modulation of multidrug resistant cells using a microfluidic chip. Anal Chem. 80:4095–4102. 2008. View Article : Google Scholar : PubMed/NCBI
5	Mundhenke C, Weigel MT, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W and Maass N: Novel treatment of ovarian cancer cell lines with imatinib mesylate combined with paclitaxel and carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol. 134:1397–1405. 2008. View Article : Google Scholar : PubMed/NCBI
6	Seeber LM and van Diest PJ: Epigenetics in ovarian cancer. Methods Mol Biol. 863:253–269. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yi C, Zhang L, Li L, Liu X, Ling S, Zhang F and Liang W: Establishment of an orthotopic transplantation tumor model in nude mice using a drug-resistant human ovarian cancer cell line with a high expression of c-Kit. Oncol Lett. 8:2611–2615. 2014.PubMed/NCBI
8	Belotte J, Fletcher NM, Awonuga AO, Alexis M, Abu-Soud HM, Saed MG, Diamond MP and Saed GM: The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer. Reprod Sci. 21:503–508. 2014. View Article : Google Scholar :
9	Fatima S, Al-Mohaimeed N, Arjumand S, Banu N, Al-Jameil N and Al-Shaikh Y: Effect of pre- and post-combined multidoses of epigallocatechin gallate and coenzyme Q10 on cisplatin-induced oxidative stress in rat kidney. J Biochem Mol Toxicol. 29:91–97. 2015. View Article : Google Scholar
10	Lin L, Zheng J, Zhu W and Jia N: Nephroprotective effect of gelsemine against cisplatin-induced toxicity is mediated via attenuation of oxidative stress. Cell Biochem Biophys. 71:535–541. 2015. View Article : Google Scholar
11	Huang C, Han Y, Wang Y, Sun X, Yan S, Yeh ET, Chen Y, Cang H, Li H, Shi G, et al: SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J. 28:2748–2762. 2009. View Article : Google Scholar : PubMed/NCBI
12	López-Lázaro M: Dual role of hydrogen peroxide in cancer: Possible relevance to cancer chemoprevention and therapy. Cancer Lett. 252:1–8. 2007. View Article : Google Scholar
13	Suzuki-Karasaki Y, Suzuki-Karasaki M, Uchida M and Ochiai T: Depolarization controls TRAIL-sensitization and tumor-selective killing of cancer cells: Crosstalk with ROS. Front Oncol. 4:1282014. View Article : Google Scholar : PubMed/NCBI
14	Wang J and Yi J: Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol Ther. 7:1875–1884. 2008. View Article : Google Scholar : PubMed/NCBI
15	Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR and Jiang BH: Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 67:10823–10830. 2007. View Article : Google Scholar : PubMed/NCBI
16	Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK and Ngan HY: Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 29:1742–1750. 2008. View Article : Google Scholar : PubMed/NCBI
17	Shigetomi H, Tsunemi T, Haruta S, Kajihara H, Yoshizawa Y, Tanase Y, Furukawa N, Yoshida S, Sado T and Kobayashi H: Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities. Cancer Invest. 30:473–480. 2012. View Article : Google Scholar : PubMed/NCBI
18	King SM, Quartuccio SM, Vanderhyden BC and Burdette JE: Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage and epithelial-stromal interaction. Carcinogenesis. 34:1125–1133. 2013. View Article : Google Scholar : PubMed/NCBI
19	Martinez-Outschoorn UE, Curry JM, Ko YH, Lin Z, Tuluc M, Cognetti D, Birbe RC, Pribitkin E, Bombonati A, Pestell RG, et al: Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4. Cell Cycle. 12:2580–2597. 2013. View Article : Google Scholar : PubMed/NCBI
20	Choi K, Ryu SW, Song S, Choi H, Kang SW and Choi C: Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ. 17:833–845. 2010. View Article : Google Scholar
21	Yi L, Zongyuan Y, Cheng G, Lingyun Z, Guilian Y and Wei G: Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci. 105:520–527. 2014. View Article : Google Scholar : PubMed/NCBI
22	Lee MW, Park SC, Kim JH, Kim IK, Han KS, Kim KY, Lee WB, Jung YK and Kim SS: The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in HeLa cells. Cancer Lett. 182:75–82. 2002. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Jin L, Li X and Deng H, Chen Y, Lian Q, Ge R and Deng H: Gossypol induces apoptosis in ovarian cancer cells through oxidative stress. Mol Biosyst. 9:1489–1497. 2013. View Article : Google Scholar : PubMed/NCBI
24	Das A, Banik NL and Ray SK: Garlic compounds generate reactive oxygen species leading to activation of stress kinases and cysteine proteases for apoptosis in human glioblastoma T98G and U87MG cells. Cancer. 110:1083–1095. 2007. View Article : Google Scholar : PubMed/NCBI
25	Lee DH, Rhee JG and Lee YJ: Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol. 157:1189–1202. 2009. View Article : Google Scholar : PubMed/NCBI
26	Powolny AA and Singh SV: Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett. 269:305–314. 2008. View Article : Google Scholar : PubMed/NCBI
27	Shenoy K, Wu Y and Pervaiz S: LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res. 69:1941–1950. 2009. View Article : Google Scholar : PubMed/NCBI
28	Pasini A and Zunino F: New cisplatin analogues - on the way to better antitumor agents. Angew Chem Int Ed Engl. 26:615–624. 1987. View Article : Google Scholar
29	Poirier MC, Lippard SJ, Zwelling LA, Ushay HM, Kerrigan D, Thill CC, Santella RM, Grunberger D and Yuspa SH: Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci USA. 79:6443–6447. 1982. View Article : Google Scholar : PubMed/NCBI
30	Wong E and Giandomenico CM: Current status of platinum-based antitumor drugs. Chem Rev. 99:2451–2466. 1999. View Article : Google Scholar
31	Calderone V, Casini A, Mangani S, Messori L and Orioli PL: Structural investigation of cisplatin-protein interactions: Selective platination of His19 in a cuprozinc superoxide dismutase. Angew Chem Int Ed Engl. 45:1267–1269. 2006. View Article : Google Scholar : PubMed/NCBI
32	DeConti RC, Toftness BR, Lange RC and Creasey WA: Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res. 33:1310–1315. 1973.PubMed/NCBI
33	Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, Xu L, Kucherlapati R and Jain RK: Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 66:3360–3364. 2006. View Article : Google Scholar : PubMed/NCBI
34	Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
35	Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF: Characterization of a cis-diammine-dichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:414–418. 1987.PubMed/NCBI
36	Bertsch U, Röder C, Kalthoff H and Trauzold A: Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: Emerging role of nuclear TRAIL-R2. Cell Death Dis. 5:e13902014. View Article : Google Scholar : PubMed/NCBI
37	Ashraf NU and Sheikh TA: Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res. 49:1405–1418. 2015. View Article : Google Scholar : PubMed/NCBI
38	Afanas'ev I: Reactive oxygen species signaling in cancer: Comparison with aging. Aging Dis. 2:219–230. 2011.